NWRN Share Price Performance
CHF 24.70
15.50 (168.48%)
Price CHF 24.70
Share Pricen/a
Newron Pharmaceuticals S.p.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 37 Fair Values set on narratives written by author
NWRN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Newron Pharmaceuticals S.p.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Mar 24, 2026
- 1.27
- 100.00%
- 42.30%
- 3,276.4%
About NWRN
- Founded
- 1999
- Employees
- 22
- CEO
- WebsiteView website
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
